@article{5caf7e50b6174e00848a0883ea6a0f78,
title = "Favorable Anti-VEGF Crunch Syndrome: Nonsurgical Relief of Vitreoretinal Traction in Eyes with Proliferative Diabetic Retinopathy and Tractional Retinal Detachment",
abstract = "Herein are reported four eyes among three patients with favorable anti-vascular endothelial growth factor crunch syndrome by which contraction of fibrovascular tissue led to relief of vitreoretinal traction without surgical intervention. This phenomenon led to complete or partial retinal reattachment in two patients with diabetic tractional retinal detachments. These cases represent favorable anatomic outcomes of crunch syndrome secondary to anti-vascular endothelial growth factor pharmacotherapy and are unique compared with most cases, which have been associated with negative outcomes.",
author = "Lee, {Irene T.} and Corona, {Stephanie Trejo} and Wong, {Tien P.} and Flynn, {Harry W.} and Wykoff, {Charles C.}",
note = "Funding Information: Financial disclosure: Irene T. Lee has grant support from the American Society of Ophthalmic Plastic and Reconstructive Surgery Foundation and Vanderbilt Eye Institute Lefkowitz Award for Vision Research. The Department of Ophthalmology at Vanderbilt Eye Institute receives grant support from Research to Prevent Blindness. Harry W. Flynn Jr. is supported in part by NIH Center Core Grant P30EY014801 (Bethesda, Maryland) and Research to Prevent Blindness Unrestricted Grant (GR004596) to the University of Miami. The Department of Ophthalmology at the University of Miami receives grant support from Research to Prevent Blindness and the National Institutes of Health. Charles C. Wykoff is a consultant for AbbVie, Adverum, Aerie, Aerpio, Alimera Sciences, Allergan, Allgenesis, Alnylam, Annexon, Apellis, Arrowhead, Bausch & Lomb, Bayer, Bionic Vision Technologies, Chengdu Kang-hong Biotechnologies, Cholgene Therapeutics, Clearside Biomedical, EyeGate, EyePoint, Genentech, Gyroscope, IVERIC Bio, Janssen, Kato, Kiora, Kodiak Sciences, Laboratoires THEA, Long Bridge Medical, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, OcuTerra, OliX, ONL Therapeutics, Opthea, Palatin, Perfuse Therapeutics, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, Stealth, Surrozen, Takeda, Valo Health, Verana Health, and Vitranu. Charles C. Wykoff conducts research with Adverum, Aerie, Aldeyra, Alimera Sciences, Alkahest, Allergan, Amgen, Annexon, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS, iRENIX, IVERIC bio, Kodiak Sciences, LMRI, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Opthea, Oxurion, Recens-Medical, Regeneron, RegenXBio, Roche, SamChunDang Pharm, Samsung Bioepis, Taiwan Liposome Company, and Xbrane BioPharma. Charles C. Wykoff owns stock in ONL Therapeutics, PolyPhotonix, RecensMedical, and Visgenx. The remaining authors report no relevant financial relationships to disclose. Publisher Copyright: {\textcopyright} Ophthalmic Surgery, Lasers & Imaging Retina.",
year = "2022",
month = aug,
doi = "10.3928/23258160-20220628-01",
language = "English (US)",
volume = "53",
pages = "455--459",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "8",
}